|
CA2669060A1
(en)
|
2006-12-01 |
2008-06-05 |
Actelion Pharmaceuticals Ltd |
Piperidine compounds
|
|
CL2007003827A1
(es)
*
|
2006-12-28 |
2008-09-26 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
|
|
CL2008000836A1
(es)
*
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
WO2008150364A1
(en)
*
|
2007-05-23 |
2008-12-11 |
Merck & Co., Inc. |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
JP4881476B2
(ja)
|
2007-05-23 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピリジルピペリジン・オレキシン受容体アンタゴニスト
|
|
ATE524466T1
(de)
|
2007-07-03 |
2011-09-15 |
Actelion Pharmaceuticals Ltd |
3-azabicycloä3.3.0üoktanverbindungen
|
|
CA2693817A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Actelion Pharmaceuticals Ltd |
Trans-3-aza-bicyclo[3.1.0]hexane derivatives
|
|
KR20100046047A
(ko)
*
|
2007-07-27 |
2010-05-04 |
액테리온 파마슈티칼 리미티드 |
2-아자-비시클로[3.3.0]옥탄 유도체
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009040730A2
(en)
*
|
2007-09-24 |
2009-04-02 |
Actelion Pharmaceuticals Ltd |
Pyrrolidines and piperidines as orexin receptor antagonists
|
|
MX2010008993A
(es)
*
|
2008-02-21 |
2010-09-07 |
Actelion Pharmaceuticals Ltd |
Derivados de 2-aza-biciclo-[2.2.1]heptano.
|
|
CN102015645B
(zh)
*
|
2008-04-30 |
2012-11-14 |
埃科特莱茵药品有限公司 |
哌啶和吡咯烷化合物
|
|
KR20110071004A
(ko)
*
|
2008-10-14 |
2011-06-27 |
액테리온 파마슈티칼 리미티드 |
페네틸아미드 유도체 및 이의 헤테로시클릭 유사체
|
|
AR074426A1
(es)
|
2008-12-02 |
2011-01-19 |
Glaxo Group Ltd |
Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
|
|
JP2012510494A
(ja)
*
|
2008-12-02 |
2012-05-10 |
グラクソ グループ リミテッド |
Ｎ−｛［（ｉｒ、４ｓ、６ｒ）−３−（２−ピリジニルカルボニル）−３−アザビシクロ［４．１．０］ヘプタ−４−イル］メチル｝−２−ヘテロアリールアミン誘導体およびその使用
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
WO2010078348A1
(en)
*
|
2008-12-29 |
2010-07-08 |
Vanderbilt University |
3.1.0 bicyclic glyt1 inhibitors and methods of making and using same
|
|
WO2010122151A1
(en)
*
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
|
|
EP2275421A1
(en)
|
2009-07-15 |
2011-01-19 |
Rottapharm S.p.A. |
Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
|
|
WO2011023578A1
(en)
|
2009-08-24 |
2011-03-03 |
Glaxo Group Limited |
5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
|
|
WO2011023585A1
(en)
|
2009-08-24 |
2011-03-03 |
Glaxo Group Limited |
Piperidine derivatives used as orexin antagonists
|
|
ES2585806T3
(es)
|
2009-10-23 |
2016-10-10 |
Janssen Pharmaceutica N.V. |
Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
|
|
EP2496578A4
(en)
|
2009-11-05 |
2013-08-21 |
Univ Notre Dame Du Lac |
IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
|
|
BR112012016201A2
(pt)
*
|
2009-12-29 |
2017-12-19 |
Suven Life Sciences Ltd |
''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
|
|
WO2012039371A1
(ja)
*
|
2010-09-22 |
2012-03-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
シクロプロパン化合物
|
|
CN103201261A
(zh)
*
|
2010-11-10 |
2013-07-10 |
埃科特莱茵药品有限公司 |
用作为食欲素受体拮抗剂的内酰胺衍生物
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
ES2672732T3
(es)
|
2012-02-07 |
2018-06-15 |
Eolas Therapeutics Inc. |
Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
ITMI20120424A1
(it)
*
|
2012-03-19 |
2013-09-20 |
Rottapharm Spa |
Composti chimici
|
|
KR101689093B1
(ko)
|
2012-06-04 |
2016-12-22 |
액테리온 파마슈티칼 리미티드 |
벤즈이미다졸-프롤린 유도체
|
|
US9605002B2
(en)
*
|
2012-07-18 |
2017-03-28 |
University Of Notre Dame Du Lac |
5,5-heteroaromatic anti-infective compounds
|
|
BR112015007516A2
(pt)
|
2012-10-10 |
2017-07-04 |
Actelion Pharmaceuticals Ltd |
antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
|
|
CA2902135A1
(en)
|
2013-03-12 |
2014-09-18 |
Actelion Pharmaceuticals Ltd |
Azetidine amide derivatives as orexin receptor antagonists
|
|
WO2014159061A2
(en)
|
2013-03-14 |
2014-10-02 |
Janssen Pharmaceutica Nv |
Benzo-fused heterocyclic derivatives useful as agonists of gpr120
|
|
US20160279098A1
(en)
*
|
2013-11-11 |
2016-09-29 |
Euthymics Bioscience, Inc. |
Novel methods
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
HK1225731B
(en)
|
2013-12-03 |
2017-09-15 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
|
|
HRP20181710T1
(hr)
|
2013-12-04 |
2018-12-28 |
Idorsia Pharmaceuticals Ltd |
Uporaba derivata benzimidazol-prolina
|
|
JP6663909B2
(ja)
|
2014-08-13 |
2020-03-13 |
エオラス セラピューティクス， インコーポレイテッド |
オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
|
|
MX376164B
(es)
|
2014-10-23 |
2025-03-07 |
Eisai R&D Man Co Ltd |
Composiciones y metodos para tratar el insomnio.
|
|
KR20180053386A
(ko)
|
2015-09-17 |
2018-05-21 |
마빈 제이. 밀러 |
마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
|
|
MX2018009656A
(es)
|
2016-02-12 |
2019-02-20 |
Astrazeneca Ab |
Piperidinas halo-sustituidas como moduladores de los receptores de orexinas.
|
|
US10828302B2
(en)
|
2016-03-10 |
2020-11-10 |
Janssen Pharmaceutica Nv |
Methods of treating depression using orexin-2 receptor antagonists
|
|
US20190151304A1
(en)
|
2016-05-10 |
2019-05-23 |
Inserm (Institut National De La Santé Et De La Rechercjae Médicale |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
|
|
HRP20211304T1
(hr)
|
2017-05-03 |
2021-11-12 |
Idorsia Pharmaceuticals Ltd |
Pripravljanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020007977A1
(en)
|
2018-07-06 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
7-trifluoromethyl-[1,4]diazepan derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
JP7681113B2
(ja)
*
|
2021-02-02 |
2025-05-21 |
メッドシャイン ディスカバリー インコーポレイテッド |
テトラヒドロピロロ環化合物及びその使用
|
|
AR129309A1
(es)
|
2022-05-13 |
2024-08-07 |
Idorsia Pharmaceuticals Ltd |
Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
|
|
CN117126101A
(zh)
*
|
2023-08-28 |
2023-11-28 |
瑞博(杭州)医药科技有限公司 |
一种脯氨酸结构的盐酸盐中间体的高效制备方法
|
|
WO2025224168A1
(en)
|
2024-04-24 |
2025-10-30 |
Idorsia Pharmaceuticals Ltd |
Aryl sulfone and sulfanone derivatives as orexin receptor modulators
|